Summary
BeiGene, Ltd. (ONC) filed an 8-K on July 26, 2018, primarily announcing significant progress across its drug development pipeline. Key updates include the FDA granting Fast Track Designation for zanubrutinib in Waldenström macroglobulinemia, suggesting potential for expedited review. The company also reported on the initiation of pivotal Phase 3 trials for pamiparib in gastric cancer and for tislelizumab (in combination with chemotherapy) in non-small cell lung cancer. Furthermore, preliminary topline results from a Phase 2 trial of tislelizumab for Chinese patients with relapsed/refractory classical Hodgkin’s lymphoma were announced. These developments highlight BeiGene's active clinical development programs and strategic efforts to advance its oncology pipeline, potentially leading to future commercial opportunities.
Key Highlights
- 1FDA granted Fast Track Designation for zanubrutinib for the treatment of Waldenström macroglobulinemia, indicating potential for accelerated approval.
- 2BeiGene intends to pursue accelerated approval for zanubrutinib in WM based on Phase 1 trial results.
- 3First patient dosed in a global Phase 3 clinical trial of pamiparib as maintenance therapy for gastric cancer patients who responded to first-line chemotherapy.
- 4First patient dosed in a Phase 3 pivotal clinical trial of tislelizumab combined with chemotherapy as a first-line treatment for non-squamous non-small cell lung cancer in China.
- 5Preliminary topline results reported from the independent review of response data from a pivotal Phase 2 trial of tislelizumab in Chinese patients with relapsed/refractory classical Hodgkin’s lymphoma.
- 6Entered into a 2018 Consulting Agreement with co-founder and Scientific Advisory Board Chairman, Dr. Xiaodong Wang, for scientific and strategic advisory services through December 31, 2020, with an annual fee of $100,000.